New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
09:11 EDTYRCW, SQNM, BIIB, SGMO, MCK, ROVI, QIHU, BBBY, DG, FDO, ICPT, JCP, MOn The Fly: Pre-market Movers
HIGHER: Macy's (M), up 6% after announcing cost reduction initiatives that include cutting 2,500 jobs and issuing FY14 EPS guidance that beat the consensus analyst estimate... Intercept (ICPT), up over 200% after announcing NASH primary endpoint met, FLINT trial stopped early... J.C. Penney (JCP), up 3% after upgraded at Piper Jaffray... McKesson (MCK), up 3.7% after making final offer for Celesio, increases price to EUR 23.50 per share... Sangamo (SGMO), up 14.3% after collaborating with Biogen (BIIB) for hemoglobinopathy treatment development... Sequenom (SQNM), up 10.6% after granted patent by European patent office... DOWN AFTER EARNINGS: Family Dollar (FDO), down 7.3%. Peer Dollar General (DG) down 2.4% in sympathy... Bed Bath & Beyond (BBBY), down 9%... Rovi (ROVI), down 3.4%. ALSO LOWER: Qihoo 360 (QIHU), down 4.5% after China Daily reported the company denied Alibaba's interested in investing... YRC Worldwide (YRCW), down 13% after Teamsters group says union contract extension may be defeated.
News For M;JCP;ICPT;FDO;DG;BBBY;QIHU;ROVI;MCK;SGMO;BIIB;SQNM;YRCW From The Last 14 Days
Check below for free stories on M;JCP;ICPT;FDO;DG;BBBY;QIHU;ROVI;MCK;SGMO;BIIB;SQNM;YRCW the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 23, 2014
09:50 EDTBIIBBiogen says strategic bias still tuck-in acquisitions
Subscribe for More Information
09:37 EDTBIIBBiogen says 'clearly' has considered tax inversion
Subscribe for More Information
09:25 EDTBIIBBiogen sees Japan as an attractive growth opportunity for company
Says remains committed to SG&A leverage in 2014. Says guidance assumes Tecfidera EU uptake similar to U.S.
09:17 EDTBIIBOn The Fly: Pre-market Movers
Subscribe for More Information
09:05 EDTBIIBBiogen says received letter from EU saying PLEGRIDY has been approved
Subscribe for More Information
09:02 EDTMMacy's reports new initiates in multi-year program to enhance sustainability
Subscribe for More Information
08:56 EDTBIIBBiogen still sees FY CapEx approximately $300M
Believes TECFIDERA is on track to become the leading MS product in the U.S. Says outside the U.S., demand for TECFIDERA has been broad; launch trajectories similar to experience in U.S. Continues to be in discussions with AIFA to resolve its dispute on Tysabri for February 2009-January 2013. Says FY guidance "meaningfully increased" due primarily to the  growth  of  TECFIDERA in the U.S. and the EU., the strength of our other MS therapies and clarity on the AIFA pricing matter. Comments from slides that will be presented on the Q2 earnings conference call.
06:50 EDTBIIBBiogen raises FY14 EPS to $12.90-$13.10 from $11.35-$11.45, consensus $11.53
Subscribe for More Information
06:48 EDTBIIBBiogen reports Q2 Tecfidera revenue $700M; Reports Q2 Avonex revenue $774M
Subscribe for More Information
06:47 EDTBIIBBiogen reports Q2 adjusted EPS $3.49, consensus $2.83
Reports Q2 revenue $2.42B, consensus $2.16B; Non-GAAP diluted EPS was benefited by approximately 15c, following the approval from an agreement with the Italian National Medicines Agency relating to Tysabri sales in Italy.
July 22, 2014
14:30 EDTBIIBBiogen technical remarks ahead of earnings
Subscribe for More Information
July 21, 2014
16:00 EDTDGOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
13:23 EDTDGHigh option volume stocks: RFMD LCI MR PII DG CTRL
Subscribe for More Information
11:21 EDTSQNMSequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg
Subscribe for More Information
07:37 EDTBIIBBiogen July weekly volatility elevated into Q2 and outlook
Biogen July weekly call option implied volatility is at 55, August is at 34, October is at 36; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 on July 23.
07:02 EDTSQNMSequenom subsidiary launched VisibiliT test in international markets
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch the VisibiliT laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score.
July 18, 2014
18:12 EDTMVisa, MasterCard denied bid to dismiss opt-out swipe fee suits, Bloomberg says
Merchants that opted out of the swipe-fee settlement brought their own suits, which Visa (V) and MasterCard (MA) were not approved to dismiss, Bloomberg reports. Merchants such as Target (TGT) and Macy’s (M) pursued their cases after dropping out of an earlier settlement over swipe fees, Bloomberg added. Reference Link
10:40 EDTJCPJ.C. Penney call active on renewed takeover chatter
Subscribe for More Information
10:28 EDTJCPRumor: J.C. Penney moves up on renewed takeover chatter
08:45 EDTQIHUDefined mobile strategy could serve as catalyst for Qihoo 360, says UBS
UBS is optimistic about Qihoo 360's growth momentum in search and mobile, but believes a better defined mobile strategy could serve as a catalyst for the shares. The firm sees a margin squeeze in Q2 but an anticipated pickup in search monetization should support margin recovery. UBS has a Buy rating with a $155 price target on Qihoo.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use